Medtronic to Acquire SPR Therapeutics for $650 Million
Advertisement
The acquisition is expected to close later this year, subject to customary regulatory approvals and closing conditions. The move reflects Medtronic’s continued focus on advancing neuromodulation solutions and addressing unmet needs in chronic pain care, a condition affecting millions globally.
Medtronic has announced its intent to acquire SPR Therapeutics in a deal valued at $650 million as part of its strategy to expand treatment options for patients living with chronic pain.
The acquisition is expected to close later this year, subject to customary regulatory approvals and closing conditions. The move reflects Medtronic’s continued focus on advancing neuromodulation solutions and addressing unmet needs in chronic pain care, a condition affecting millions globally.
Medtronic, headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, US, said the acquisition will strengthen its pain management portfolio by integrating SPR Therapeutics’ neurostimulation technology. SPR Therapeutics, based in Cleveland, Ohio, focuses on developing minimally invasive therapies for pain relief.
The acquisition, announced in May 2026, is expected to close later this year, subject to customary regulatory approvals and closing conditions. The move reflects Medtronic’s continued focus on advancing neuromodulation solutions and addressing unmet needs in chronic pain care, a condition affecting millions globally.
SPR Therapeutics is known for its proprietary SPRINT Peripheral Nerve Stimulation (PNS) System, which is designed to provide non-opioid pain relief through a short-term implant. By bringing this technology into its portfolio, Medtronic aims to broaden its offerings beyond traditional long-term implants and provide more flexible treatment options for physicians and patients.
In its announcement, Medtronic stated, “This acquisition expands care options for people living with chronic pain,” highlighting the company’s intent to enhance patient access to innovative therapies. The deal also aligns with the growing demand for alternatives to opioid-based pain management, as healthcare systems increasingly prioritize safer and more sustainable treatment approaches.
The acquisition underscores a broader trend of consolidation in the medical technology sector, where companies are investing in advanced therapeutic solutions to improve outcomes and expand market reach.
Stay tuned for more such updates on Digital Health News
